[go: up one dir, main page]

WO2014118808A3 - Ticagrelor solid dispersion - Google Patents

Ticagrelor solid dispersion Download PDF

Info

Publication number
WO2014118808A3
WO2014118808A3 PCT/IN2014/000079 IN2014000079W WO2014118808A3 WO 2014118808 A3 WO2014118808 A3 WO 2014118808A3 IN 2014000079 W IN2014000079 W IN 2014000079W WO 2014118808 A3 WO2014118808 A3 WO 2014118808A3
Authority
WO
WIPO (PCT)
Prior art keywords
ticagrelor
solid dispersion
amorphous solid
solvent
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000079
Other languages
French (fr)
Other versions
WO2014118808A2 (en
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Kesireddy Subash Chander Reddy
Katham SRINIVASA REDDY
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2014118808A2 publication Critical patent/WO2014118808A2/en
Anticipated expiration legal-status Critical
Publication of WO2014118808A3 publication Critical patent/WO2014118808A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel amorphous solid dispersion of ticagrelor in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. Specifically, provided is a process for the preparation of amorphous solid dispersion of ticagrelor which comprises: a) preparing a solution comprising a mixture of ticagrelor and one or more pharmaceutically acceptable carriers selected from copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in a solvent; and b) removing the solvent to obtain amorphous solid dispersion of ticagrelor in the carrier.
PCT/IN2014/000079 2013-02-04 2014-01-31 Ticagrelor solid dispersion Ceased WO2014118808A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN468/CHE/2013 2013-02-04
IN468CH2013 2013-02-04

Publications (2)

Publication Number Publication Date
WO2014118808A2 WO2014118808A2 (en) 2014-08-07
WO2014118808A3 true WO2014118808A3 (en) 2015-08-27

Family

ID=51263087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000079 Ceased WO2014118808A2 (en) 2013-02-04 2014-01-31 Ticagrelor solid dispersion

Country Status (1)

Country Link
WO (1) WO2014118808A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104434805B (en) * 2013-09-22 2017-09-29 成都盛迪医药有限公司 A kind of ticagrelor solid dispersions and preparation method thereof
CN104193747B (en) * 2014-08-12 2016-05-11 许彩霞 The unbodied preparation of ADZ6140
TR201601835A2 (en) * 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi PRODUCTION METHOD FOR FORMULATIONS CONTAINING TIKAGRELOR
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
WO2020021110A1 (en) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Pharmaceutical composition of ticagrelor
US20240285636A1 (en) * 2021-06-14 2024-08-29 Libbs Farmacêutica Ltda Pharmaceutical composition and use of the pharmaceutical composition
WO2024021802A1 (en) * 2022-07-27 2024-02-01 江苏慧聚药业股份有限公司 Solid ticagrelor dispersion, method for preparing same, and use thereof
CN116916928B (en) * 2022-07-27 2025-11-28 江苏慧聚药业股份有限公司 Ticagrelor solid dispersion, and preparation method and application thereof
WO2024199129A1 (en) * 2023-03-24 2024-10-03 江苏慧聚药业股份有限公司 Ticagrelor sustained-release composition and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293513A1 (en) * 2000-06-02 2007-12-20 Astrazeneca Ab Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20130028938A1 (en) * 2009-12-23 2013-01-31 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2013150495A2 (en) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293513A1 (en) * 2000-06-02 2007-12-20 Astrazeneca Ab Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound
US20100210719A1 (en) * 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20130028938A1 (en) * 2009-12-23 2013-01-31 Ratiopharm Gmbh Solid pharmaceutical dosage form
WO2013150495A2 (en) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor

Also Published As

Publication number Publication date
WO2014118808A2 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
WO2014118808A3 (en) Ticagrelor solid dispersion
PH12017502315A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
CL2012002355A1 (en) Compounds derived from 1,3,4,8-tetrahydro-2h-pyrido [1,2-a] pyrazine; pharmaceutical composition that includes them; pharmaceutical kit; and its use as hiv integrase inhibitors for the treatment of an infectious hiv disease.
NZ721952A (en) Delayed release compositions of linaclotide
EP3626253A3 (en) Stable formulations of linaclotide
AR102926A1 (en) ANTI-TARGET COMPOSITIONS
IN2013MU03583A (en)
BR112019024747A2 (en) fixed dose formulations
HK1221418A1 (en) Hydrogel-linked prodrugs releasing modified drugs
EP4360621A3 (en) Formulations of bendamustine
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
HK1208441A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
CR20150297A (en) COMICRONIZATION PRODUCT THAT INCLUDES ULIPRISTAL ACETATE
UA105285C2 (en) Solid pharmaceutical composition comprising ramipril and amlodipine besilate and method for its preparation
WO2015002755A3 (en) Compounds for the treatment of malaria
HK1212978A1 (en) Novel derivatives of sinapinic acid
WO2013171766A3 (en) Saxagliptin solid dispersion
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
WO2012164575A3 (en) Amorphous ritonavir co-precipitated
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
HK1223852A1 (en) Testosterone gel compositions and related methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14745995

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14745995

Country of ref document: EP

Kind code of ref document: A2